124 related articles for article (PubMed ID: 37748002)
1. Changes of Serum C-Reactive Protein Level in Patients With Depressive Disorders After Treatment With Agomelatine Combined With Aerobic Exercise and Its Significance.
Sun Z; Chen S; Zhang H; Gu X; Ge H; Chen J
Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):192-197. PubMed ID: 37748002
[TBL] [Abstract][Full Text] [Related]
2. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
4. Major depressive disorder, anhedonia and agomelatine: an open-label study.
Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
[TBL] [Abstract][Full Text] [Related]
5. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.
Gorwood P; Benichou J; Moore N; Wattez M; Secouard MC; Desobry X; Picarel-Blanchot F; de Bodinat C
Clin Drug Investig; 2020 Nov; 40(11):1009-1020. PubMed ID: 32729068
[TBL] [Abstract][Full Text] [Related]
7. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
8. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.
Martinotti G; Sepede G; Gambi F; Di Iorio G; De Berardis D; Di Nicola M; Onofrj M; Janiri L; Di Giannantonio M
J Clin Psychopharmacol; 2012 Aug; 32(4):487-91. PubMed ID: 22722509
[TBL] [Abstract][Full Text] [Related]
10. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
Gupta K; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
J Clin Pharmacol; 2017 Dec; 57(12):1519-1526. PubMed ID: 28833192
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
[TBL] [Abstract][Full Text] [Related]
13. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
15. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Lôo H; Hale A; D'haenen H
Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
[TBL] [Abstract][Full Text] [Related]
17. Treatment response and cognitive impairment in major depression: association with C-reactive protein.
Chang HH; Lee IH; Gean PW; Lee SY; Chi MH; Yang YK; Lu RB; Chen PS
Brain Behav Immun; 2012 Jan; 26(1):90-5. PubMed ID: 21839826
[TBL] [Abstract][Full Text] [Related]
18. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
Kennedy SH; Avedisova A; Belaïdi C; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2016 Feb; 26(2):378-389. PubMed ID: 26708320
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms.
Martinotti G; Pettorruso M; De Berardis D; Varasano PA; Lucidi Pressanti G; De Remigis V; Valchera A; Ricci V; Di Nicola M; Janiri L; Biggio G; Di Giannantonio M
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26775293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
